Moderna : Une rentabilité qui s’éloigne à 2028
>mRNA-4157 devra attendre ses résultats de phase 3 - Hier après-midi, Moderna organisait son CMD qui a permis de remettre en exergue les priorités du groupe et ainsi sa guidance financière. L’évolution CT du portefeuille produits implique malheureusement un décalage dans son estimation de « break even » qui passe de 2026 à 2028 (cf ci-dessous). En commençant par les points positifs, nous pouvons souligner le dépôt d’enregistrement de mRNA-1283 (nouvelle génératio...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.